Table 2. Pair-wise meta-analyses of direct comparisons between the eight drugs.
| Endpoints | Direct comparisons | I2 | Tau2 | PH values | HR (95% CI) | PH values |
|---|---|---|---|---|---|---|
| OS | TMZ vs. Placebo | 51.8% | 0.076 | 0.081 | 0.78 (0.56, 1.11) | 0.168 |
| PCV vs. Placebo | 0.00% | 0.000 | 0.517 | 0.81 (0.65, 1.02) | 0.070 | |
| Nimotuzumab vs. Placebo | - | - | - | 0.68 (0.42, 1.11) | 0.120 | |
| DBD+BCNU vs. Placebo | - | - | - | 0.77 (0.56, 1.06) | 0.108 | |
| BEV+TMZ vs. TMZ | - | - | - | 0.88 (0.76, 1.02) | 0.089 | |
| Cilengitide+TMZ vs. TMZ | 70.90% | 0.056 | 0.064 | 0.86 (0.58, 1.26) | 0.427 | |
| TMZ+ACNU+CDDP vs. TMZ | - | - | - | 0.52 (0.24, 1.12) | 0.096 | |
| DMFO+PCV vs. PCV | - | - | - | 1.00 (0.91, 1.11) | 1.000 | |
| PFS | TMZ vs. Placebo | 80.90% | 0.242 | 0.000 | 0.87 (0.53, 1.43) | 0.581 |
| PCV vs. Placebo | 0.00% | 0.000 | 0.582 | 0.65 (0.53, 0.80) | 0.000 | |
| Nimotuzumab vs. Placebo | - | - | - | 0.75 (0.49, 1.15) | 0.191 | |
| DBD+BCNU vs. Placebo | - | - | - | 0.75 (0.57, 0.99) | 0.041 | |
| BEV+TMZ vs. TMZ | - | - | - | 0.64 (0.55, 0.74) | 0.000 | |
| Cilengitide+TMZ vs. TMZ | 0.00% | 0.000 | 0.523 | 0.90 (0.76, 1.06) | 0.217 | |
| TMZ+ACNU+CDDP vs. TMZ | - | - | - | 0.89 (0.49, 1.62) | 0.702 | |
| DMFO+PCV vs. PCV | - | - | - | 1.00 (0.91, 1.11) | 1.000 |
*H: heterogeneity; HR: hazard ratio; CI: confidence interval; OS: overall survive; PFS: progression-free survival; TMZ: Temozolomide; PCV: Procarbazine, Lomustine, and Vincristine; DBD: Dibromodulcitol; BCNU: Carmustine; BEV: Bevacizumab; ACNU: Nimustine; CDDP: Cisplatin; DMFO: Eflornithine;